Cargando…

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer

Irinotecan (CPT-11) is widely used for the treatment of unresectable colorectal cancer in combination with fluoropyrimidines, such as 5-fluorouracil and S-1. Diarrhea is one of the adverse effects associated with CPT-11 and frequently reported by patients treated with CPT-11-containing regimens comb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okunaka, Mashiro, Kano, Daisuke, Matsui, Reiko, Kawasaki, Toshikatsu, Uesawa, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073045/ https://www.ncbi.nlm.nih.gov/pubmed/33921605 http://dx.doi.org/10.3390/ph14040377

Ejemplares similares

Comprehensive Analysis of Chemotherapeutic Agents That Induce Infectious Neutropenia
por: Okunaka, Mashiro, et al.
Publicado: (2021)

Nuclear Receptor and Stress Response Pathways Associated with Antineoplastic Agent-Induced Diarrhea
por: Okunaka, Mashiro, et al.
Publicado: (2022)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Herbal Medicines for Irinotecan-Induced Diarrhea
por: Tang, Liu, et al.
Publicado: (2019)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis
por: Funasaka, Chikako, et al.
Publicado: (2021)

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis()()
por: Erdem, Zeynep N., et al.
Publicado: (2017)

Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy
por: Okunaka, Mashiro, et al.
Publicado: (2021)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
por: Yue, Bei, et al.
Publicado: (2021)

Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer
por: Lu, Hongyang, et al.
Publicado: (2018)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
por: Kan, Yusuke, et al.
Publicado: (2021)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer
por: Trumpi, K., et al.
Publicado: (2015)

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2017)

Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer
por: Buck, Emanuel, et al.
Publicado: (2019)

Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer
por: Pliakou, Evangelia, et al.
Publicado: (2022)

Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats
por: Deng, Chao, et al.
Publicado: (2017)

Clinical Study on Prevention of Irinotecan-Induced Delayed-Onset Diarrhea by Hot Ironing with Moxa Salt Packet on Tianshu and Shangjuxu
por: Lai, Xianghong, et al.
Publicado: (2022)

Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database
por: Hosoya, Ryuichiro, et al.
Publicado: (2017)

Analysis of Factors Associated with Hiccups Using the FAERS Database
por: Hosoya, Ryuichiro, et al.
Publicado: (2021)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Alliot, C, et al.
Publicado: (2004)

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
por: Huang, Jiao-Ren, et al.
Publicado: (2019)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Analysis of Corticosteroid-Induced Glaucoma Using the Japanese Adverse Drug Event Reporting Database
por: Kawabe, Ayano, et al.
Publicado: (2023)

Vitamin A Ameliorated Irinotecan-Induced Diarrhea in a Piglet Model Involving Enteric Glia Modulation and Immune Cells Infiltration
por: Li, Meng, et al.
Publicado: (2022)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress
por: Marx, Christian, et al.
Publicado: (2022)

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2004)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

A fatal myelosuppression, diarrhea and neurotoxicity induced by combination of irinotecan and tegafur-gimeracil-oteracil potassium in the treatment of colon cancer: a case report
por: Liu, Yang-Xi, et al.
Publicado: (2020)

Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions
por: Kurosaki, Kota, et al.
Publicado: (2021)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review
por: Ozawa, Shogo, et al.
Publicado: (2021)

Irinotecan-Induced Steatohepatitis: Current Insights
por: Han, Jun, et al.
Publicado: (2021)

Systematic evaluation of irinotecan-induced intestinal mucositis based on metabolomics analysis
por: Yu, Qing-Qing, et al.
Publicado: (2022)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_n8ciot2rjtvoks5c6fdinicj4g